Price Target Cut to $136; Abbott Details Phased Retirement Program
Citi cut Abbott’s price target by $4 to $136 while maintaining a Buy rating, noting healthy medtech sector fundamentals despite recent volatility. Separately, Abbott’s Freedom to Work program lets employees aged 55+ with over 10 years’ tenure reduce to four days weekly or take five extra weeks off.
1. Price Target Revision
An analyst lowered Abbott’s price target from $140 to $136 while maintaining a Buy rating, noting healthy medtech sector fundamentals despite recent volatility. The adjustment reflects revised expectations after fourth-quarter results and positions Abbott competitively within its medical technology peers.
2. Phased Retirement Program
Abbott’s Freedom to Work program allows employees aged 55 or older with over 10 years’ tenure to reduce their schedule to four days per week or receive up to five additional weeks off annually. This phased retirement offering supports workforce retention, addresses financial and health insurance needs, and caters to employees delaying full retirement.